To develop a new therapeutic strategy against thyroid cancer (TC), the expression of both substance P (SP) and neurokinin-1 receptor (NK-1R) must be demonstrated in TC cells. This study aims to examine by immunohistochemistry, the localization of SP and the NK-1R in human TC samples (papillary, follicular, medullary, anaplastic), in metastasis and in healthy thyroid samples. SP and the NK-1R were expressed in all normal and TC samples. In healthy glands, SP was located in follicular cells (nucleus) and colloid and NK-1R in follicular cells (cytoplasm) and stroma. In TC samples, SP was visualized in follicular cells (nucleus and cytoplasm), stroma and colloid and NK-1R in follicular cells (cytoplasm), stroma and colloid. A semiquantitative scoring system (Allred Unit Scoring System) was applied. The expression (Allred total score) of SP and NK-1R was weaker in normal thyroid glands than in TC. In comparison with TC samples, a lower intensity/proportion of SP (nucleus and cytoplasm of follicular cells; stroma) was observed in normal samples. By contrast, in the colloid of TC samples the presence of SP was lower than in normal samples. In comparison with TC samples, the presence of the NK-1R in the cytoplasm of follicular cells and colloid was lower in normal thyroid samples, whereas the expression of this receptor in the stroma was higher. The results reported in this study suggest that the NK-1R could be a new target for the treatment of TC and use of the NK-1R antagonists could serve as a new anti-TC therapeutic strategy.

中文翻译：

---

人类甲状腺癌中P物质和Neurokinin-1受体系统的免疫组织化学研究。

要开发针对甲状腺癌（TC）的新治疗策略，必须在TC细胞中证明P物质（SP）和神经激肽-1受体（NK-1R）的表达。这项研究旨在通过免疫组织化学检查在人类TC样本（乳头，滤泡，髓质，间变性），转移灶和健康甲状腺样本中SP和NK-1R的定位。SP和NK-1R在所有正常和TC样品中均表达。在健康的腺体中，SP位于卵泡细胞（细胞核）和胶体中，而NK-1R位于卵泡细胞（细胞质）和间质中。在TC样品中，SP在卵泡细胞（细胞核和细胞质），基质和胶体中可见，而NK-1R在卵泡细胞（细胞质），基质和胶体中可见。应用半定量计分系统（Allred Unit Scoring System）。正常甲状腺中SP和NK-1R的表达（Allred总分）较TC弱。与TC样品相比，在正常样品中观察到了更低的SP强度/比例（卵泡细胞的核和细胞质；基质）。相反，在TC样品的胶体中，SP的含量低于正常样品。与TC样品相比，正常甲状腺样品的滤泡细胞和胶体细胞质中NK-1R的含量较低，而基质中该受体的表达较高。这项研究报告的结果表明，NK-1R可能成为TC治疗的新靶标，而NK-1R拮抗剂的使用可以作为一种新的抗TC治疗策略。在正常样品中观察到较低的SP强度/比例（滤泡细胞的核和细胞质；基质）。相反，在TC样品的胶体中，SP的含量低于正常样品。与TC样品相比，正常甲状腺样品的滤泡细胞和胶体细胞质中NK-1R的含量较低，而基质中该受体的表达较高。这项研究报告的结果表明，NK-1R可能成为TC治疗的新靶标，而NK-1R拮抗剂的使用可以作为一种新的抗TC治疗策略。在正常样品中观察到较低的SP强度/比例（滤泡细胞的核和细胞质；基质）。相反，在TC样品的胶体中，SP的含量低于正常样品。与TC样品相比，正常甲状腺样品的滤泡细胞和胶体细胞质中NK-1R的含量较低，而基质中该受体的表达较高。这项研究报告的结果表明，NK-1R可能成为TC治疗的新靶标，而NK-1R拮抗剂的使用可以作为一种新的抗TC治疗策略。正常甲状腺样品中，卵泡细胞和胶体细胞质中NK-1R的含量较低，而基质中该受体的表达较高。这项研究报告的结果表明，NK-1R可能成为TC治疗的新靶标，而NK-1R拮抗剂的使用可以作为一种新的抗TC治疗策略。正常甲状腺样品中，卵泡细胞和胶体细胞质中NK-1R的含量较低，而基质中该受体的表达较高。这项研究报告的结果表明，NK-1R可能成为TC治疗的新靶标，而NK-1R拮抗剂的使用可以作为一种新的抗TC治疗策略。